Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash from Operations (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Cash from Operations for 2 consecutive years, with 23119000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 211.45% to 23119000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 56302000.0 through Dec 2025, up 45.28% year-over-year, with the annual reading at 56302000.0 for FY2025, 45.28% up from the prior year.
  • Cash from Operations hit 23119000.0 in Q4 2025 for Prelude Therapeutics, up from 19115000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 23119000.0 in Q4 2025 to a low of 34231000.0 in Q1 2025.